In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > REGULATORY
REGULATORY
- First Committee to Discuss Approval of New Gout Treatment Topiroxostat
April 18, 2013
- Committee Finds No Problem with Quality of 8 Generic Versions of Pfizer Japan’s Unasyn-S Kit
April 18, 2013
- “Japanese Version of CTEP” Proposed at 1st Meeting of Expert Council on Future Cancer Research
April 16, 2013
- Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
- PAFSC’s Second Committee to Review Chugai’s Breast Cancer Drug Pertuzumab on April 25
April 15, 2013
- Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
- Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
- Cost-Effective Assessment Should Be Reflected in Pricing, Not Used as Criterion for Approval: Healthcare Reps at CSIMC
April 12, 2013
- CSIMC OKs NHI Price Listing of JT’s Anti-HIV Drug Stribild on Emergency Basis
April 11, 2013
- New Flu Act to Take Effect on April 13
April 11, 2013
- Japan Launches Strategic Fund for Drug R&D in Developing World
April 10, 2013
- MHLW Issues Order for Improvement to 5 Generic Companies due to GMP Violations by South Korean Supplier
April 9, 2013
- MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
- Expert Council on Cancer Research of MHLW, MEXT, METI to Hold 1st Meeting on April 15 to Discuss Future Cancer Research Strategy
April 8, 2013
- Eisai’s HTA-Savvy Tsuchiya Picked as CSIMC Expert Member
April 5, 2013
- FPMAJ Calls for PAL Amendment to Allow Applications Based on Information in Public Domain for Ultra-Orphan Drugs
April 5, 2013
- HIB Director-General Kikura Calls for Discussions on Pricing Rules for Combination Products Containing OTC Drugs
April 5, 2013
- Astem Pres. Yoshimura Says Wholesalers Should Break Away from Dependence on Long-Listed Drugs
April 4, 2013
- Prime Minister Abe Asks Ministries to Begin Discussions Toward Establishing Japanese Version of NIH
April 2, 2013
- Hodanren Calls for Inclusion of Pharmacies’ Technical Fees in Domestic Drug Prices When Comparing Drug Prices in Japan, US, and Europe
April 1, 2013
ページ
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…